RxDoctor Payments Data

Luis Lopez, MD

Internal Medicine · Salina, KSNPI 1760895395

Payments from drug & device makers

$3,442in general payments, 2019–2025

Across 20 payments — averaging $172.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Onmark, Inc.$3K
  • US Oncology Corporate, Inc.$68
  • Amgen$37
  • Merck$23
  • Johnson & Johnson$22
  • Medtronic$20
  • plus $50 from 3 others

What the payments were for

  • Travel & lodging$1,76551%
  • Food & beverage$1,65848%
  • Gifts$201%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Onmark, Inc.10$3,223
US Oncology Corporate, Inc.2$68
Amgen2$37
Merck1$23
Johnson & Johnson1$22
Medtronic1$20
Sanofi Pasteur Inc.1$19
Pfizer1$18
Genentech USA, Inc.1$13

How this compares

$3,442 in reported general payments places this provider in the 85th percentile of 705 internal medicine providers in Kansas.

See all internal medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$1,772
Medicare patients
12
Services billed
21

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin121$118,667
OzempicSemaglutide73$93,417
Synjardy XrEmpagliflozin/Metformin Hcl88$87,046
EliquisApixaban82$80,715
TrulicityDulaglutide49$62,976
Trelegy ElliptaFluticasone/Umeclidin/Vilanter78$55,715
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$45,011
MyrbetriqMirabegron82$43,737
MounjaroTirzepatide37$42,846
RybelsusSemaglutide19$38,057
XareltoRivaroxaban46$33,291
Xigduo XrDapaglifloz Propaned/Metformin46$30,896
FarxigaDapagliflozin Propanediol40$29,870
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$17,729
Amlodipine-AtorvastatinAmlodipine/Atorvastatin112$13,871

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$80,71582 claims
Johnson & JohnsonXarelto$22$33,29146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 705 internal medicine providers in Kansas.

Other internal medicine in Salina

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →